Attruby is a medicine for adults whose heart is damaged by transthyretin amyloidosis, where a protein builds up in the heart muscle. It is taken as a pill. It works by holding the protein together so it is less likely to break apart and form harmful clumps.
Every report comes from a Lived member, sent anonymously.
Have you tried Attruby (Acoramidis) for Amyloidosis?
Acoramidis, sold as Attruby, is a prescription tablet for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). In this condition, a blood protein called transthyretin breaks apart, misfolds and builds up as stiff deposits (amyloid) in the heart muscle. The heart muscle becomes thick and stiff, so it cannot fill and pump normally, and over time this leads to heart failure. Attruby is approved for both main forms of ATTR-CM: the wild-type form, which is linked to aging and is most common in men over 60, and the variant (hereditary) form, caused by an inherited change in the transthyretin gene. Its approved purpose is to reduce deaths from heart causes and hospital stays for heart problems. It is one of several medicines for ATTR-CM. Tafamidis (Vyndaqel or Vyndamax) is another tablet-form stabilizer, and vutrisiran (Amvuttra) is an injection that lowers how much transthyretin the liver makes. These medicines slow the disease rather than remove amyloid already in the heart, so they sit alongside the usual heart failure care, not in place of it.
Transthyretin is made mainly in the liver and normally circulates as a stable group of four identical pieces, carrying thyroid hormone and vitamin A through the blood. When that four-part structure comes apart, the single pieces can misfold and clump into amyloid. This coming apart is the slow, limiting step in the whole process. Acoramidis binds to transthyretin at the spot where thyroid hormone normally sits and holds the four pieces together, so fewer break away to form new deposits. Blood tests in the main trial showed near-complete stabilization within about a month. Because it prevents new amyloid rather than clearing old deposits, the benefit shows up as slower worsening over months to years, not as a quick change in how a person feels.
Attruby comes as a 356 mg tablet. The usual dose is two tablets (712 mg) taken by mouth twice a day, with or without food. Swallow the tablets whole; do not cut, crush or chew them. Keep them in the original blister card until use, since it protects them from moisture. No dose change is needed for older age, and kidney problems did not change how the body handles the drug. How liver disease affects the drug has not been studied, which is worth raising with the prescriber if it applies. Published trial reports describe the same dose as 800 mg of acoramidis hydrochloride, which is the weight of the salt form, not a different dose.
Side effects were uncommon in the main trial. The ones seen more often than with placebo in the main trial were diarrhea (about 12 in 100 people, compared with about 8 in 100 on placebo) and pain in the upper stomach area (about 6 in 100, compared with about 1 in 100). These were mostly mild and usually went away without stopping the medicine. Diarrhea or stomach pain that does not settle is worth a call to the care team. About the same share of people stopped treatment because of side effects on acoramidis as on placebo, roughly 9 in 100 in each group.
Some medicines speed up the body's breakdown of acoramidis and can lower its levels enough to weaken it. The label says to avoid combining it with these. Examples include the tuberculosis antibiotic rifampin, the seizure medicines carbamazepine and phenytoin, and the herbal supplement St. John's wort. Acoramidis can also raise the levels of some other medicines that the liver clears through an enzyme called CYP2C9, so the prescriber may watch those more closely. Give the care team and pharmacist a full list of prescriptions, over-the-counter medicines and supplements before starting. There are no listed contraindications and no boxed warning. Too little is known about use during pregnancy or breastfeeding to judge its safety, and it has not been studied in children. Anyone who becomes pregnant or thinks they may be pregnant while taking it should tell their prescriber right away.
Acoramidis is a long-term treatment. In the main trial, which followed adults with ATTR-CM for 30 months, 19 in 100 people taking acoramidis died compared with 26 in 100 on placebo, and fewer were admitted to the hospital for heart problems (27 in 100 compared with 43 in 100). People on acoramidis also kept more of their walking ability and reported better day-to-day heart failure symptoms than those on placebo. Continued follow-up of trial participants suggests that people who started earlier kept that advantage through four and a half years. The benefit shows up as fewer hospital stays and slower decline, so it may not be something a person feels directly. The disease still progresses in many people, more slowly, so regular heart follow-up continues, often with blood tests such as NT-proBNP (a marker of strain on the heart) and assessments of breathing and activity. Two blood test changes are expected and are not signs of harm. Creatinine, a kidney blood test, usually rises slightly in the first four weeks and then levels off, and it returns to baseline if the medicine is stopped. A thyroid test called free thyroxine may read lower without any real change in thyroid function, because acoramidis occupies the protein that normally carries that hormone.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Attruby (Acoramidis), what you've noticed, or ask the community a question.